Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.

Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN.

Front Oncol. 2019 Jan 22;8:670. doi: 10.3389/fonc.2018.00670. eCollection 2018.

2.

Brain distribution of a panel of EGFR inhibitors using cassette-dosing in wild-type and Abcb1/Abcg2 deficient mice.

Kim M, Laramy JK, Mohammad AS, Talele S, Fisher J, Sarkaria JN, Elmquist WF.

Drug Metab Dispos. 2019 Jan 31. pii: dmd.118.084210. doi: 10.1124/dmd.118.084210. [Epub ahead of print]

3.

Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.

Gampa G, Kim M, Mohammad AS, Parrish KE, Mladek AC, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2019 Mar;368(3):446-461. doi: 10.1124/jpet.118.253708. Epub 2019 Jan 8.

PMID:
30622172
4.

Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior.

Chen JE, Pedron S, Shyu P, Hu Y, Sarkaria JN, Harley BAC.

Front Mater. 2018 Jun;5. pii: 39. doi: 10.3389/fmats.2018.00039. Epub 2018 Jun 26.

PMID:
30581816
5.

Drug and disease signature integration identifies synergistic combinations in glioblastoma.

Stathias V, Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, Durante MA, Williams SL, Harbour JW, Volmar CH, Lyons NJ, Wahlestedt C, Graham RM, Ivan ME, Komotar RJ, Sarkaria JN, Subramanian A, Golub TR, Schürer SC, Ayad NG.

Nat Commun. 2018 Dec 14;9(1):5315. doi: 10.1038/s41467-018-07659-z.

6.

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL, Johnson AJ, Lu FK, Xie XS, Joughin BA, Reddy RJ, Peng S, Abdelmoula WM, Jackson PR, Kolluri A, Kellersberger KA, Agar JN, Lauffenburger DA, Swanson KR, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR.

Nat Commun. 2018 Nov 21;9(1):4904. doi: 10.1038/s41467-018-07334-3.

7.

Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system.

Walb MC, Carlson BL, Sarkaria JN, Tryggestad EJ.

Br J Radiol. 2018 Nov 14:20180487. doi: 10.1259/bjr.20180487. [Epub ahead of print]

PMID:
30299986
8.

Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.

Unruh D, Mirkov S, Wray B, Drumm M, Lamano J, Li YD, Haider QF, Javier R, McCortney K, Saratsis A, Scholtens DM, Sarkaria JN, James CD, Horbinski C.

Clin Cancer Res. 2019 Jan 15;25(2):747-759. doi: 10.1158/1078-0432.CCR-18-1222. Epub 2018 Sep 28.

PMID:
30266764
9.

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.

Oliva CR, Halloran B, Hjelmeland AB, Vazquez A, Bailey SM, Sarkaria JN, Griguer CE.

Cell Commun Signal. 2018 Sep 19;16(1):61. doi: 10.1186/s12964-018-0273-7.

10.

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.

Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.

Mol Cancer Ther. 2018 Nov;17(11):2462-2472. doi: 10.1158/1535-7163.MCT-18-0470. Epub 2018 Aug 30.

PMID:
30166399
11.

Investigating Dependencies of Relative Biological Effectiveness for Proton Therapy in Cancer Cells.

Howard ME, Beltran C, Anderson S, Tseung WC, Sarkaria JN, Herman MG.

Int J Part Ther. 2018 Winter;4(3):12-22. doi: 10.14338/IJPT-17-00031.1. Epub 2018 Mar 21.

12.

Hypoxia-inducible factor 2α: a novel target in gliomas.

Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE.

Future Med Chem. 2018 Sep 1;10(18):2227-2236. doi: 10.4155/fmc-2018-0163. Epub 2018 Aug 9.

PMID:
30089425
13.

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.

Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, Ligon KL, Sarkaria JN, Gygi SP, Michor F, Mitchison TJ, Charest A.

Nat Commun. 2018 Aug 6;9(1):3116. doi: 10.1038/s41467-018-05036-4.

14.

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.

Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, Kitange GJ, He L, Hu Z, Parney IF, Meyer FB, Giannini C, Sarkaria JN, Zhang Z.

Nat Commun. 2018 Jul 27;9(1):2949. doi: 10.1038/s41467-018-05373-4.

15.

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF.

Pharm Res. 2018 Jul 12;35(9):177. doi: 10.1007/s11095-018-2455-9. Review.

PMID:
30003344
16.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2018 Sep;17(9):1893-1901. doi: 10.1158/1535-7163.MCT-17-0600. Epub 2018 Jul 3.

PMID:
29970480
17.

H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.

Fang D, Gan H, Cheng L, Lee JH, Zhou H, Sarkaria JN, Daniels DJ, Zhang Z.

Elife. 2018 Jun 22;7. pii: e36696. doi: 10.7554/eLife.36696.

18.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132. doi: 10.1093/jnci/djy033.

PMID:
29788332
19.

Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.

Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, Sarkaria JN, Sondel PM, Tran PT, Wilson GD, Willers H, Wong RKS, Harari PM.

Lancet Oncol. 2018 May;19(5):e240-e251. doi: 10.1016/S1470-2045(18)30096-2. Review.

PMID:
29726389
20.

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.

Linninger A, Hartung GA, Liu BP, Mirkov S, Tangen K, Lukas RV, Unruh D, James CD, Sarkaria JN, Horbinski C.

Neuro Oncol. 2018 Aug 2;20(9):1197-1206. doi: 10.1093/neuonc/noy051.

PMID:
29660019
21.

Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues.

Zhou D, Alver BM, Li S, Hlady RA, Thompson JJ, Schroeder MA, Lee JH, Qiu J, Schwartz PH, Sarkaria JN, Robertson KD.

Genome Biol. 2018 Mar 27;19(1):43. doi: 10.1186/s13059-018-1420-6.

22.

Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition.

Herrera-Perez RM, Voytik-Harbin SL, Sarkaria JN, Pollok KE, Fishel ML, Rickus JL.

PLoS One. 2018 Mar 22;13(3):e0194183. doi: 10.1371/journal.pone.0194183. eCollection 2018.

23.

Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival.

Lassak A, Dean M, Wyczechowska D, Wilk A, Marrero L, Trillo-Tinoco J, Boulares AH, Sarkaria JN, Del Valle L, Peruzzi F, Ochoa A, Reiss K.

Mol Cell Biol. 2018 Apr 30;38(10). pii: e00608-17. doi: 10.1128/MCB.00608-17. Print 2018 May 15.

24.

Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.

Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2018 May;365(2):249-261. doi: 10.1124/jpet.117.246116. Epub 2018 Feb 12.

PMID:
29440450
25.

Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.

Drug Metab Dispos. 2018 May;46(5):658-666. doi: 10.1124/dmd.117.079194. Epub 2018 Feb 2.

PMID:
29437873
26.

LPA signaling is regulated through the primary cilium: a novel target in glioblastoma.

Loskutov YV, Griffin CL, Marinak KM, Bobko A, Margaryan NV, Geldenhuys WJ, Sarkaria JN, Pugacheva EN.

Oncogene. 2018 Mar;37(11):1457-1471. doi: 10.1038/s41388-017-0049-3. Epub 2018 Jan 11.

27.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

PMID:
29313954
28.

Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics.

Pedron S, Polishetty H, Pritchard AM, Mahadik BP, Sarkaria JN, Harley BAC.

MRS Commun. 2017 Sep;7(3):442-449. doi: 10.1557/mrc.2017.85. Epub 2017 Sep 12.

29.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA.

Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub 2017 Nov 30.

30.

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF.

Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Review.

31.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

PMID:
29016887
32.

Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma: An Alternative Detection Method for a Heterogeneous Process.

Ida CM, Butz ML, Jenkins RB, Sarkaria JN, Kitange GJ, Giannini C, Kipp BR.

Am J Clin Pathol. 2017 Oct 1;148(4):296-307. doi: 10.1093/ajcp/aqx073.

PMID:
28967952
33.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

34.

CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.

Avril T, Etcheverry A, Pineau R, Obacz J, Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, Decker PA, Sarkaria JN, Vauléon E, Chiforeanu DC, Clavreul A, Mosser J, Chevet E, Quillien V.

Clin Cancer Res. 2017 Dec 1;23(23):7360-7374. doi: 10.1158/1078-0432.CCR-17-1549. Epub 2017 Sep 22.

35.

Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.

Müller-Greven G, Carlin CR, Burgett ME, Ahluwalia MS, Lauko A, Nowacki AS, Herting CJ, Qadan MA, Bredel M, Toms SA, Lathia JD, Hambardzumyan D, Sarkaria JN, Hamerlik P, Gladson CL.

Clin Cancer Res. 2017 Nov 15;23(22):7059-7071. doi: 10.1158/1078-0432.CCR-17-0249. Epub 2017 Sep 14.

36.

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2017 Nov;363(2):136-147. doi: 10.1124/jpet.117.243477. Epub 2017 Aug 28.

37.

Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma.

Pedron S, Hanselman JS, Schroeder MA, Sarkaria JN, Harley BAC.

Adv Healthc Mater. 2017 Nov;6(21). doi: 10.1002/adhm.201700529. Epub 2017 Aug 2.

38.

Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.

Pharmacol Res. 2017 Sep;123:10-25. doi: 10.1016/j.phrs.2017.06.008. Epub 2017 Jun 17.

39.

A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.

Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA.

Nat Neurosci. 2017 Aug;20(8):1074-1084. doi: 10.1038/nn.4584. Epub 2017 Jun 12.

40.

Challenges in the delivery of therapies to melanoma brain metastases.

Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF.

Curr Pharmacol Rep. 2016 Dec;2(6):309-325. doi: 10.1007/s40495-016-0072-z. Epub 2016 Nov 9.

41.

EGFR Signals through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion.

Misek SA, Chen J, Schroeder L, Rattanasinchai C, Sample A, Sarkaria JN, Gallo KA.

Mol Cancer Res. 2017 Aug;15(8):1085-1095. doi: 10.1158/1541-7786.MCR-16-0318. Epub 2017 May 9.

42.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

43.

Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix.

Heim JB, Squirewell EJ, Neu A, Zocher G, Sominidi-Damodaran S, Wyles SP, Nikolova E, Behrendt N, Saunte DM, Lock-Andersen J, Gaonkar KS, Yan H, Sarkaria JN, Krendel M, van Deursen J, Sprangers R, Stehle T, Böttcher RT, Lee JH, Ordog T, Meves A.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3933-3938. doi: 10.1073/pnas.1614894114. Epub 2017 Mar 27.

44.

Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.

Mamo T, Mladek AC, Shogren KL, Gustafson C, Gupta SK, Riester SM, Maran A, Galindo M, van Wijnen AJ, Sarkaria JN, Yaszemski MJ.

Biochem Biophys Res Commun. 2017 Apr 29;486(2):307-313. doi: 10.1016/j.bbrc.2017.03.033. Epub 2017 Mar 12.

45.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.

46.

Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.

Bijangi-Vishehsaraei K, Reza Saadatzadeh M, Wang H, Nguyen A, Kamocka MM, Cai W, Cohen-Gadol AA, Halum SL, Sarkaria JN, Pollok KE, Safa AR.

J Neurosurg. 2017 Dec;127(6):1219-1230. doi: 10.3171/2016.8.JNS161197. Epub 2017 Jan 6.

47.

DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.

Nagel ZD, Kitange GJ, Gupta SK, Joughin BA, Chaim IA, Mazzucato P, Lauffenburger DA, Sarkaria JN, Samson LD.

Cancer Res. 2017 Jan 1;77(1):198-206. doi: 10.1158/0008-5472.CAN-16-1151. Epub 2016 Oct 28.

48.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

49.

Network Modeling Identifies Patient-specific Pathways in Glioblastoma.

Tuncbag N, Milani P, Pokorny JL, Johnson H, Sio TT, Dalin S, Iyekegbe DO, White FM, Sarkaria JN, Fraenkel E.

Sci Rep. 2016 Jun 29;6:28668. doi: 10.1038/srep28668.

50.

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.

Lescarbeau RS, Lei L, Bakken KK, Sims PA, Sarkaria JN, Canoll P, White FM.

Mol Cancer Ther. 2016 Jun;15(6):1332-43. doi: 10.1158/1535-7163.MCT-15-0692. Epub 2016 May 17.

Supplemental Content

Loading ...
Support Center